Related Experiment Videos
High-dose methylphenidate treatment of attention deficit hyperactivity disorder in a preschooler
Paul H Lipkin1, Arlene M Butz, Meira A Cozen
1Department of Pediatrics, The Kennedy Krieger Institute, Johns Hopkins University School of Medicine, 707 North Broadway, Baltimore, MD 21205, USA. lipkin@kennedykrieger.org
Insights
Preschoolers with attention deficit hyperactivity disorder (ADHD) may need higher methylphenidate doses than typically recommended. Careful monitoring is essential to balance behavioral improvements with side effects like weight loss.
Area of Science:
- Pediatric Psychiatry
- Pharmacology
- Neurodevelopmental Disorders
Background:
- Attention deficit hyperactivity disorder (ADHD) diagnosis in preschoolers lacks clear stimulant dosing guidelines.
- Methylphenidate (MPH) is a common stimulant treatment for ADHD.
Observation:
- A 4-year-old boy with ADHD received a high dose of extended-release methylphenidate (OROS MPH) at 6.1 mg/kg/day.
- Significant behavioral improvements were observed with the high-dose MPH regimen.
Findings:
- Despite behavioral gains, the patient experienced weight loss due to anorexia, a common side effect.
- The dose was reduced to 3.7 mg/kg/day (72 mg/day OROS MPH).
- This case suggests some young children may require higher MPH doses than weight-based calculations predict.
Implications:
- Clinicians must individualize MPH dosing for preschoolers with ADHD.
- Balancing therapeutic benefits against adverse effects, such as appetite suppression, is crucial.
- Further research is needed to establish optimal dosing strategies for this population.
Abstract:
Although attention deficit hyperactivity disorder is thought to be present in preschoolers, there are no clear guidelines for dosing stimulant medications in this population. This is a case of a 4-year-old boy who was given 108 mg/day extended-release methylphenidate (OROS) MPH) (6.1 mg/kg/day) by his caregiver with notable behavioral improvement. However, weight loss incurred due to the anorexic side effect of the medication led the clinician to decrease his dose to 72 mg/day OROS MPH (3.7 mg/kg/day). The case highlights that some young children with attention deficit hyperactivity disorder treated with MPH may require higher doses than would be predicted by weight-based dosing. An increased frequency of side effects associated with high doses of MPH necessitates that the clinician balance the positive behavioral response of the medication with adverse side effects in determining ideal dose.